Contact

 

Prof. Dr. med. Andreas Schneeweiss
Phone: +49 6221 5636051
Fax: +49 6221 567920

E-mail: andreas.schneeweiss@med.uni-heidelberg.de

 

 

Never say...

 

die.

Division Gynecologic Oncology

 

Our group/department has:

  • Detection of prognostic and predictive markers (Breast Cancer Res Treat 2013, Clin Cancer Res 2012, Int J Cancer 2012),
  • Establishment of new treatment strategies like a. Mechanism of targeted therapeutics (Henjes, Oncogenesis 2012), b. Dose-dense approaches (J Natl Cancer Inst 2013), novel agents (Ann Oncol 2011, Eur J Cancer 2010, Lancet Oncology 2013, Ann Oncol 2013, J Clin Oncol 2010), and c. Intensity-modulated whole abdominal radiotherapy (Int J Radiat Oncol Biol Phys 2010),
  • First reporting of outcome data of a certified breast cancer unit (Breast 2012),
  • Demonstration of circulating tumor cells containing metastases-initiating cells (Baccelli et al. Nat Biotechnol 2013), and
  • Application of targeted proteomics for biomarker discovery (Sonntag et al. European patent application).

2010 – 2013

  • Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31(6):539-44
  • Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013; 137(2):503-10
  • Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24(9):2278-84
  • Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 2012; 18(21):5972-82
  • Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S & Sahin Ö. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Molecular Systems Biology 2011; 8, 570.

Bundesministerium für Bildung und Forschung (BMBF)

  • IG Cellular Systems Genomics in Health and Disease (IG-CSG)
  • Breast Cancer Systems Biology (BreastSys) within Medical Systems-Biology (MedSys) program
  • BioRN – Biotechnologie-Cluster „Zellbasierte und molekulare Medizin“ Rhein-Neckar

Deutsche Forschungsgemeinschaft (DFG)

  • Deutsch-Israelische Projektkooperation (DIP)

Deutsches Krebsforschungszentrum (DKFZ)

  • Heidelberger Institute of Personalized Oncology (HIPO)


Nationales Centrum für Tumorerkrankungen (NCT)

  • Interdisziplinäres Forschungsprogramm des NCT
  • Heidelberg institute for stem cell technology (HI-STEM)